Medline Tracy Warehouse Destroyed in Fire; Short-Term Disruption Expected
The company is activating contingency plans, which may cause short-term supply disruptions. Analysts expect limited long-term impact.
/ 1651 items
#XY↓
MBX Biosciences’ Canvuparatide Shows Solid One-Year Data but Misses Market Expectations
MBX reports 57% response at 1 year for canvuparatide in hypoparathyroidism with stable safety, but shares fell on modest results.
Avalo Therapeutics Stock: BofA Sees 156% Upside with New Buy Rating
Strong analyst support for abdakibart in hidradenitis suppurativa as Avalo advances to Phase 3.
Adial Pharmaceuticals Acquires Azora and Raises Up to $64 Million for New Ulcerative Colitis Drug
Adial Pharmaceuticals acquires Azora Therapeutics and raises up to $64 million to advance AT177, a novel colon-targeted therapy for ulcerative colitis. Phase 1 studies planned for mid-2027.
5 Hot Biotech Stocks With Fresh Buy Ratings
Analysts initiate coverage with Buy ratings on Sensei (SNSE), Septerna (SEPN), Kazia (KZIA), NervGen (NGEN), and Sutro (STRO).
Enliven Therapeutics’ ELVN-001 Delivers Strong Results in Phase 1 CML Study, Aligns with FDA on Phase 3 Design
Early results show performance that is comparable to a widely used Novartis blockbuster and a Merck-owned experimental treatment.